Rheum Nurse Nwsl Vol 4, Iss2 Post-Test

RHEUMATOLOGY NURSE NEWSLETTER VOLUME 4, ISSUE 2
ACTIVITY LEARNING ASSESSMENT REQUEST FOR CREDIT & EVALUATION FORM

Simply complete the following survey, which will be reviewed by Institute educators upon receipt.

Activity Instructions & Criteria for Success

Continuing Nursing Education contact hours are offered to all activity participants. To successfully complete this activity and obtain a Certificate of Contact Hours awarded, the learner is required to read the entire newsletter, complete the post-test, and complete the activity evaluation form. Learners are required to correctly answer 80% of the learning assessment questions. Statements of Credit will be forwarded via email within 4 to 6 weeks. All forms must be received by October 1, 2012, to be eligible for credit.

Question Title

* 1. Approximately what percentage of patients with PsA develop progressive disease that leads to structural joint damage?

25%

40%

50%

75%

Question Title

* 2. JG is a 35-year-old female patient who you are seeing for the first time. She has significant pain, morning stiffness of approximately 70 minutes each morning that improves with activity, synovitis, elevated ESR, CRP, and RF, osteopenia, and marginal joint erosion. Based upon this limited information, which of the following inflammatory diseases does she most likely have?

Psoriatic arthritis

Rheumatoid arthritis

Osteoarthritis

Reactive arthritis

Question Title

* 3. Which of the following statements is not true?

Joint symptoms alone are not a reliable tool for distinguishing PsA from other types of inflammatory arthritis

PsA typically develops within 7-10 years after the onset of psoriasis

All patients with PsA have psoriasis

All patients with psoriasis have PsA

Question Title

* 4. How does the evidence supporting the use of phototherapy in patients with moderate to severe PsA compare to the evidence supporting the use of MTX and biologic DMARDs in these patients?

There is a higher level of evidence supporting the use of phototherapy in these patients

There is lower level of evidence supporting the use of phototherapy in these patients

There is the same level of evidence supporting the use of phototherapy in these patients

There is no evidence supporting the use of phototherapy in these patients

Question Title

* 5. Evidence clearly shows that the increased risk of skin cancer among patients with PsA is due to which of the following factors?

Underlying symptoms of the condition

Phototherapy

Use of biologic agents

None of the above

Question Title

* 6. TL, a 44-year-old male patient, presents with a family history of psoriasis but no current psoriatic skin or scalp disease, dactylitis, juxtaarticlular new bone formation, rheumatoid factor positivity, and no psoriatic nail dystrophy. According to CASPAR criteria, should he be diagnosed with PsA?

Yes

Not enough information is presented to make a clear determination

Question Title

* 7. For which PsA patient group is the use of the PASI score most relevant?

Those who prioritize skin improvement as a major treatment goal

Those who priority reduction in pain as a major treatment goal

Those with skin involvement that primarily affects the shoulders and neck

Those whose activities of daily living are most severely affected by the disease

Question Title

* 8. Which of the following is indicated as treatment for mild PsA?

Full-dose systemic corticosteroids

Phototherapy

Methotrexate

NSAIDs

Question Title

* 9. Biologic agents indicated for use in both psoriasis and PsA include which of the following?

Rituximab

Etanercept

Certolizumab pegol

Golimumab

Question Title

* 10. Folic acid is often recommended for patients with PsA prescribed which of the following agents?

Infliximab

Adalimumab

Ustekinumab

Methotrexate

Question Title

* 11. After participating in this activity, I am better able to:

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Strongly disagree	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Disagree	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Neutral	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Agree	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Strongly agree
Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Strongly disagree	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Disagree	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Neutral	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Agree	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Strongly agree
Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Strongly disagree	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Disagree	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Neutral	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Agree	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Strongly agree

Question Title

* 12. Relative to each objective, do you plan to change your practice?

	Yes	No	Already Doing
Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Yes	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis No	Identify common clinical, physical, and extraarticular features of PsA that differentiate the condition from other types of inflammatory arthritis Already Doing
Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Yes	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months No	Appraise the relevance of various clinically validated PsA disease assessment and monitoring tools, and implement one or more into your practice as warranted within the next three months Already Doing
Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Yes	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA No	Assess recent evidence on current and emerging agents used to treat mild, moderate, and severe PsA Already Doing

Question Title

* 13. Approximately, how many patients with PsA do you treat and/or manage on a monthly basis?

Less than 3 patients

3-5 patients

6-10 patients

More than 10 patients

Question Title

* 14. What is your primary practice setting?

Hospital

University/academic medical center

Clinic

Private practice

Group or staff model health maintenance organization

Other (please specify)

Question Title

* 15. How many years have you been in practice as a rheumatology nurse?

0-5 years

6-10 years

11-15 years

16 or more years

Question Title

* 16. Was disclosure information provided to you at the beginning of this activity?

Yes

Question Title

* 17. Did this activity promote a particular company or product?

Yes

If yes, please explain in detail

Question Title

* 18. Number of credits claimed (Maximum credits=1.25 ANCC-COA contact hours/1.5 California Board of Nursing contact hours)

	Please choose one
Contact hours requested	Contact hours requested Please choose one menu

Question Title

* 19. Please enter the following information

Name

Address:

City/Town:

State:

ZIP:

Email Address:

Phone Number: